NICE says yes to Servier's Procoralan, but only after other treatments
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published draft guidance adding Servier's Procoralan (ivabradine) to the list of treatments available for patients with chronic heart failure. The draft guidance is largely in line with 2012 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure and, according to NICE, it reflects the "robust" evidence supporting existing treatments.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.